All In Biotech

Drug Trial Radar · NCT07883421

Immunogenicity of Standard-Dose Versus High-Dose Influenza Vaccines in Older Adults in Singapore

Evaluating the Year-Round Immunogenicity of Standard-Dose Versus High-Dose Seasonal Influenza Vaccines in Adults Aged 60 Years or Older in Singapore

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Mar 2027

Study completion Mar 2028

Sponsor

Lead sponsor
Tan Tock Seng HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
A*STAR Infectious Diseases Labs; World Health Organization Collaborating Centre for Reference and Research on Influenza (WHOCCRRI)
First posted
Oct 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the high-dose influenza vaccine can improve year-round protection in older adults aged 60 years and above. The main question it aims to answer is: • Can the high-dose influenza vaccine induce higher antibody titres at Day 14 post-vaccination compared to standard-dose influenza vaccine? Participants will: * Receive one dose of either the high-dose or standard-dose influenza vaccine * Be followed for one year, with four scheduled visits * Keep a diary of their symptoms for 3 days after vaccination * Report symptoms whenever they experience an acute respiratory infection (ARI), self-perform lateral flow assay (LFA) testing capable of detecting influenza A and B, and send nasal swabs for central testing

Conditions

  • Influenza

Interventions

  • High-dose influenza vaccineBiological

    Each dose contains 60 mcg haemagglutinin of each of the 3 influenza vaccine strains.

  • Standard-dose influenza vaccineBiological

    Each dose contains 15 mcg haemagglutinin of each of the 3 influenza vaccine strains.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GMT ratio (HD-IIV/SD-IIV) for A/H3N2 strain in the vaccineTime frame: Day 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Centre for Infectious Diseases (NCID)

    Singapore, Singapore

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.